The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

October 4, 2024

Study Completion Date

December 31, 2024

Conditions
Huntington Disease
Interventions
DRUG

ER2001 injection

The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.

Trial Locations (1)

510080

RECRUITING

First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ExoRNA Bioscience

INDUSTRY